Manuel Ramos

3.4k total citations
65 papers, 1.3k citations indexed

About

Manuel Ramos is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Manuel Ramos has authored 65 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 25 papers in Cancer Research and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Manuel Ramos's work include Cancer Treatment and Pharmacology (25 papers), Breast Cancer Treatment Studies (25 papers) and HER2/EGFR in Cancer Research (18 papers). Manuel Ramos is often cited by papers focused on Cancer Treatment and Pharmacology (25 papers), Breast Cancer Treatment Studies (25 papers) and HER2/EGFR in Cancer Research (18 papers). Manuel Ramos collaborates with scholars based in Spain, Switzerland and United States. Manuel Ramos's co-authors include Miguel Martín, Lourdes Calvo, Rafael Fábregas, Sergi Vidal, Manuel Fraile, Antonio Moral, Montserrat Solá, Emilio Alba, Aňa Lluch and Encarna Adrover and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Manuel Ramos

63 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manuel Ramos Spain	16	846	688	313	288	229	65	1.3k
R. Largillier France	14	940 1.1×	527 0.8×	231 0.7×	334 1.2×	201 0.9×	47	1.5k
G. Walsh United Kingdom	20	827 1.0×	783 1.1×	379 1.2×	289 1.0×	201 0.9×	39	1.5k
Naveen Faridi Pakistan	24	570 0.7×	345 0.5×	311 1.0×	265 0.9×	291 1.3×	85	1.4k
G. Le Bouëdec France	19	570 0.7×	699 1.0×	435 1.4×	169 0.6×	435 1.9×	90	1.7k
S. David Nathanson United States	19	642 0.8×	344 0.5×	175 0.6×	159 0.6×	172 0.8×	41	1.2k
Fausto Maffini Italy	21	658 0.8×	581 0.8×	382 1.2×	389 1.4×	616 2.7×	71	1.6k
Giovanna Masci Italy	21	789 0.9×	526 0.8×	126 0.4×	376 1.3×	121 0.5×	73	1.6k
Masujiro Makita Japan	18	447 0.5×	588 0.9×	500 1.6×	156 0.5×	244 1.1×	69	1.0k
Carl M. Sutherland United States	19	815 1.0×	499 0.7×	301 1.0×	249 0.9×	158 0.7×	42	1.4k
Gerhard Gebauer Germany	23	854 1.0×	517 0.8×	134 0.4×	227 0.8×	205 0.9×	49	1.4k

Countries citing papers authored by Manuel Ramos

Since Specialization

Citations

This map shows the geographic impact of Manuel Ramos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Ramos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Ramos more than expected).

Fields of papers citing papers by Manuel Ramos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Ramos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Ramos. The network helps show where Manuel Ramos may publish in the future.

Co-authorship network of co-authors of Manuel Ramos

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Ramos. A scholar is included among the top collaborators of Manuel Ramos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Ramos. Manuel Ramos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aznar, María Luisa, Juan Espinosa‐Pereiro, Manuel Ramos, et al.. (2024). A non-randomized pragmatic historically controlled trial evaluating the effectiveness and safety of a bedaquiline or a linezolid-based short regimen for rifampicin-resistant tuberculosis. Journal of Infection. 89(6). 106291–106291. 1 indexed citations

Tibau, Ariadna, María Teresa Martínez, Manuel Ramos, et al.. (2023). Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Therapeutic Advances in Medical Oncology. 15. 4287560953–4287560953. 8 indexed citations

Jiménez, M. Martín, Christoph Zielinski, Manuel Ruíz‐Borrego, et al.. (2021). 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study. Annals of Oncology. 32. S457–S458. 3 indexed citations

Tibau, Ariadna, María Teresa Martínez, Manuel Ramos, et al.. (2021). 94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study. Annals of Oncology. 32. S63–S63. 2 indexed citations

Templeton, Arnoud J., Álvaro Rodríguez-Lescure, A. Ruíz, et al.. (2018). Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. Clinical & Translational Oncology. 20(12). 1548–1556. 10 indexed citations

Cueva, Juan, Silvia Antolín, Lourdes Calvo, et al.. (2017). Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention. Clinical & Translational Oncology. 19(9). 1067–1078. 10 indexed citations

Llombart‐Cussac, Antonio, Manuel Ramos, E. Dalmau, et al.. (2016). Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study. European Journal of Cancer. 58. 122–129. 6 indexed citations

Ramos, Manuel, et al.. (2014). Intraoperative ultrasound in conservative surgery for non-palpable breast cancer after neoadjuvant chemotherapy. International Journal of Surgery. 12(6). 572–577. 26 indexed citations

Alba, Emilio, Joan Albanell, Juan de la Haba-Rodríguez, et al.. (2014). Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. British Journal of Cancer. 110(5). 1139–1147. 55 indexed citations

10.

Ramos, Manuel, et al.. (2014). La biopsia del ganglio centinela después de quimioterapia neoadyuvante en el cáncer de mama. Relación con los subtipos moleculares. Revista Española de Medicina Nuclear e Imagen Molecular. 33(6). 340–345. 4 indexed citations

11.

Ramos, Manuel, et al.. (2012). Ultrasound-guided excision combined with intraoperative assessment of gross macroscopic margins decreases the rate of reoperations for non-palpable invasive breast cancer. The Breast. 22(4). 520–524. 48 indexed citations

12.

Servitja, Sònia, Manuel Ramos, Miguel Gil Gil, et al.. (2011). Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2. Anti-Cancer Drugs. 23(2). 239–246. 7 indexed citations

13.

Martín, Miguel, Pedro Sánchez‐Rovira, Montserrat Muñoz-Mateu, et al.. (2011). Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–05 study. Annals of Oncology. 22(12). 2591–2596. 26 indexed citations

14.

Puente, Javier, Sara López‐Tarruella, Amparo Ruı́z, et al.. (2010). Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. Breast Cancer Research and Treatment. 122(2). 591–600. 36 indexed citations

15.

Ramos, Manuel, et al.. (2008). Staging the Axilla with selective sentinel node biopsy in patients with previous excision of non-palpable and palpable breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 35(7). 1299–1304. 14 indexed citations

16.

Vázquez‐Estévez, Sergio, Margarita Amenedo, Luis León‐Mateos, et al.. (2007). Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02). Anti-Cancer Drugs. 18(10). 1201–1206. 2 indexed citations

17.

Martín, Miguel, Aňa Lluch, Miguel Ángel Seguí, et al.. (2006). Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Annals of Oncology. 17(8). 1205–1212. 156 indexed citations

18.

Espinosa, Ana, María Dolores Tabernero, María Carmen García-Macías, et al.. (2003). Her-2/neu Gene Amplification in Familial vs Sporadic Breast Cancer; Impact on the Behavior of the Disease. American Journal of Clinical Pathology. 120(6). 917–927. 6 indexed citations

19.

Morales, Serafín, Manuel Ramos, Miguel Méndez, et al.. (2003). Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study. Cancer Chemotherapy and Pharmacology. 53(1). 75–81. 19 indexed citations

20.

Espinosa, Ana, María Dolores Tabernero, María Carmen García-Macías, et al.. (2003). Her-2/neuGene Amplification in Familial vs Sporadic Breast Cancer. American Journal of Clinical Pathology. 120(6). 917–927. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact